A further interaction study of quinine with clinically important drugs by human liver microsomes: Determinations of inhibition constant (K(i)) and type of inhibition

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 24, Issue 3, 1999, Pages 272-278

  Zhao, Xue Jun ^a,b   Ishizaki, Takashi ^a,c  

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c KUMAMOTO UNIVERSITY   (Japan)

Author keywords

3 Hydroxylation; CYP3A; Drug interactions; Human liver microsomes; Quinine

Indexed keywords

CIMETIDINE; DILTIAZEM; DOXYCYCLINE; ERYTHROMYCIN; HYDRALAZINE; KETOCONAZOLE; NIFEDIPINE; OLEANDOMYCIN; OMEPRAZOLE; PRIMAQUINE; QUININE; TETRACYCLINE; TROLEANDOMYCIN; VERAPAMIL;

ARTICLE; CLINICAL ARTICLE; COMPETITIVE INHIBITION; DRUG BLOOD LEVEL; DRUG HYDROXYLATION; DRUG METABOLISM; HUMAN; HUMAN TISSUE; INHIBITION KINETICS; LIVER MICROSOME METABOLISM;

EID: 0033392753     PISSN: 03787966     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03190031     Document Type: Article

References (41)

1. Dyer J.R., Davis T.M.E., Giele C., Annus T., Garcia-Webb P., Robson J. (1994) : The pharmacokinetics and pharmacodynamics of quinine in the diabetic and non-diabetic elderly. Br. J. Clin. Pharmacol., 38: 205-212.
2. Hien T.T., White N.J. (1993) : Qinghaosu. Lancet, 341: 603-608.
3. Boele van Hensbroek M., Onyiprah E., Jaffar S. et al. (1996) : A trial of artemether or quinine in children with cerebral malaria. N. Engl. J. Med., 335: 69-75.
4. Hien T.T., Day N.PJ., Phu N.H. et al. (1996) : A controlled trial of artemether or quinine in Vietnamese adults with severe falciparum malaria. N. Engl. J. Med., 335: 76-83.
5. Tracy J.W., Webster L.T. (1996) : Drugs used in the chemotherapy of protozoal infections. Malaria. In: Hardman J.G., Limbird L.E., Monlinoff P.B., Ruddon R.W., Gilman A.G. (Eds) Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th Edn. New York: McGraw-Hill, 965-985.
6. White N.J. (1992) : Antimalarial pharmacokinetics and treatment regimens. Br. J. Clin. Pharmacol, 34: 1-10.
7. Krishna S., White N.J. (1996) : Pharmacokinetics of quinine, chloroquine and amodiaquine. Clin. Pharmacokinet, 30: 263-299
8. Wanwimolruk S., Wong S.M., Zhang H., Coville P.F., Walker R.J. (1995) : Metabolism of quinine in man: identification of a major metabolise, and effects of smoking and rifampicin pretreatment. J. Pharm. Pharmacol., 47: 957-963.
9. Wanwimolruk S., Wong S.M., Zhang H., Coville P.F. (1996) : Simultaneous determination of quinine and a major metabolite 3-hydroxyquinine in biological fluids by HPLC without extraction. J. Liq. Chromatogr., 19: 293-305.
10. Zhao X.J., Yokoyama H., Chiba K., Wanwimolruk S., Ishizaki T. (1996) : Identification of human cytochrome P450 isoforms involved in the 3-hydroxylation of quinine by human liver microsomes and nine recombinant human cytochromes P450. J. Pharmacol. Exp. Ther., 279: 1327-1334.
11. Zhang H., Coville P.F., Walker R.J., Miners J.O., Birkett D.J., Wanwimolruk S. (1997) : Metabolism of quinine in humans: evidence for the involvement of human CYP3A in the hepatic metabolism of quinine. Br. J. Clin. Pharmacol., 43: 245-252.
12. Wrighton S.A., Stevens J.C. (1992) : The human hepatic cytochromes P450 involved in drug metabolism. Crit. Rev. Toxicol., 22: 1-21.
13. Brockmoller J., Roots I. (1994) : Assessment of liver metabolic function: clinical implications. Clin. Pharmacokinet, 27: 216-248.
14. Andersson J. (1996) : Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lasoprazole and pantoprazole. Clin. Pharmacokinet., 31: 9-28.
15. Bradley D. (1993) : Prophylaxis against malaria for travellers from the United Kingdom. BMJ, 306: 1247-1252.
16. White N.J. (1988) : Drug treatment and prevention of malaria. Eur.J. Clin. Pharmacol., 34: 1-14.
17. Zhao X.J., Ishizaki T. (1997) : Metabolic interactions of selected antimalarial and non-antimalarial drugs with the major pathway (3-hydroxylation) of quinine in human liver microsomes. Br. J. Clin. Pharmacol., 44: 505-511.
18. Chiba K., Kobayashi K., Manabe K., Tani M., Kamataki T., Ishizaki T. (1993) : Oxidative metabolism of omeprazole in human liver microsomes: cosegregation with S-mephenytoin 4′-hydroxylation. J. Pharmacol. Exp. Ther., 266: 52-59.
19. Echizen H., Kawasaki H., Chiba K., Tani M., Ishizaki T. (1993) : A potent inhibitory effect of erythromycin and other macrolide antibiotics on the mono-N-dealkylation metabolism of disopyramide with human liver microsomes. J. Pharmacol. Exp. Ther., 82: 61-73.
20. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. (1951) : Protein measurement with the Folin phenol reagent. J. Biol. Chem., 193: 265-275.
21. Yamaoka K., Tanigawara Y., Nakagawa T., Uno J. (1981) : A pharmacokinetic analysis program (MULTI) for microcomputer. J. Pharm. Dyn., 4: 879-885.
22. Segel I.H. (1975) : Behavior and analysis of rapid equilibrium and steady-state enzyme system. In: Enzyme Kinetics New York: John Wiley, 100-226.
23. Bourrie M., Meunier V., Berger Y., Fabre G. (1996) : Cytochrome P450 isoform inhibitions as a tool for the investigation of metabolic reactions catalysed by human liver microsomes. J. Pharmacol. Exp. Ther., 277: 321-332.
24. Watkins P.B., Wrighton S.A., Maure J.P. et al. (1985) : Identification of an inducible form of cytochrome P-450 in human liver. Proc. Natl. Acad. Sci. USA, 82: 6310-6314.
25. Dollery S.C., Boobis A.R., Burley D. et al. (1991): Verapamil: pp. V12-V18, nifedipine: pp. N80-N87 and primaquine: pp. P209-P218, In: Therapeutic Drugs. London: Churchill Livingston.
26. Dollery S.C., Boobis A.R., Burley D. et al. (1991): Verapamil: pp. V12-V18, nifedipine: pp. N80-N87 and primaquine: pp. P209-P218, In: Therapeutic Drugs. London: Churchill Livingston.
27. Dollery S.C., Boobis A.R., Burley D. et al. (1991): Verapamil: pp. V12-V18, nifedipine: pp. N80-N87 and primaquine: pp. P209-P218, In: Therapeutic Drugs. London: Churchill Livingston.
28. Kapusnik-Uner J.E., Sande M.A., Chambers H.F. (1996) : Antimicrobial agents. tetracycline, chloramphenicol, erythromycin, and miscellaneous antibacterial agents. In: Hardman J.G., Limbird LE., Monlinoff P.B., Ruddon R.W., Gilman A.G. (Eds) Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th Edn. New York: McGraw-Hill, 1123-1153.
29. Karbwang J., Bangchang K.N., Thanavibul A., Wattanakoon Y., Harinasuta T. (1994) : Quinine toxicity when given with doxycycline and mefloquine. Southeast Asian J. Trop. Med. Public Health, 25: 397-400.
30. Couet W., Laroche R., Floch J.J., Istin B., Fourtillan J.B., Sauniere J.F. (1991) : Pharmacokinetics of quinine and doxycycline in patients with acute falciparum malaria: a study in Africa. Ther. Drug. Monit., 13: 496-501.
31. Andersson T., Miners J.O., Veronese M.E., Birkett D.J. (1993) : Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br. J. Clin. Pharmacol., 36: 521-530.
32. Andersson T., Miners J.O., Veronese M.E., Birkett D.J. (1994) : Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms. Br. J. Clin. Pharmacol., 38: 131-137.
33. Na Bangchang K., Karbwang J., Back D.J. (1992) : Primaquine metabolism by human liver microsomes: effect of other antimalarial drugs. Biochem. Pharmacol., 44: 587-590.
34. Maurice M., Pichard L., Daujat M. et al. (1992) : Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture. FASEB J., 6: 752-758.
35. Back D.J., Tjia J.F., Karbwang J., Colbert J. (1988) : In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolines. Br. J. Clin. Pharmacol., 26: 23-29.
36. Back D.J., Stevenson P., Tjia J.F. (1989) : Comparative effects of two antimycotic agents, ketoconazole and terbinafine, on the metabolism of tolbutamide, ethinyloestradiol, cyclosporin and ethoxycoumarin by human liver microsomes in vitro. Br. J. Clin. Pharmacol., 28: 166-170.
37. Eugster H.P., Sengstag C. (1993) : Saccharomyces cerevisae: an alternative source for human liver microsomal enzymes and its use in drug interaction studies. Toxicology, 82: 61-73.
38. Newton D.J., Wang R.W., Lu A.Y.H. (1995) : Cytochrome P450 inhibitors: evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab. Dispos., 23: 154-158.
39. Shimada J., Yamazaki H., Miura M., Inui Y., Guengerich F.P. (1994) : Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol. Exp. Ther., 270: 414-423.
40. Christians U., Schmidt G., Bader A. et al. (1996) : Identification of drugs inhibiting the in vitro metabolism of tacrolimus by human liver microsomes. Br. J. Pharmacol., 41: 187-190.
41. Irshaid Y., Branch R.A., Adedoyin A. (1996) : Metabolic interactions of putative cytochrome P4503A substrates with alternative pathways of dapsone metabolism in human liver microsomes. Drug Metab. Dispos., 24: 164-171.